Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Up 151.8% in November

Akari Therapeutics, Plc (NASDAQ:AKTX) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 56,900 shares, a growth of 151.8% from the November 15th total of 22,600 shares. Based on an average trading volume of 36,300 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.5% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Akari Therapeutics in a research report on Wednesday, December 4th. They set a “sell” rating for the company.

Akari Therapeutics Stock Performance

Shares of NASDAQ:AKTX remained flat at $1.00 during trading on Wednesday. 13,974 shares of the stock were exchanged, compared to its average volume of 23,216. Akari Therapeutics has a 52 week low of $0.90 and a 52 week high of $4.40. The firm has a 50 day simple moving average of $2.09 and a 200-day simple moving average of $2.83.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.